Fulvestrant is a drug treatment ofhormone receptor-positive metastatic breast cancer in postmenopausal women withdisease progression following anti-estrogen therapy. It is a complete estrogenreceptor antagonist with no agonist effects, which in addition, accelerates theproteasomal degradation of the estrogen receptor.
Ralington pharma LLP (India), a globalmanufacturer and supplier for Prodx for R&D, Pilot or Commercials Quantities with Pharmacopeial Grade USP/ EP/ BP/ IP/ JP/ In-House.
Prodx available with USDMF,EDMF, DMF, USFDA, EUGMP, GMP, ISOCERTIFIED,WHO-GMP and DMF as per the requirement. Product supply inStandard Packaging & labeling as per FDA along with supportivedocumentation. We can also offer Intermediates of prodx.
Molecular Formula :
Molecular Weight :
Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271 +A13(1).